• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5074186)   Today's Articles (190)
For: Madjar K, Mohindra R, Durán-Pacheco G, Rasul R, Essioux L, Maiya V, Chandler GS. Baseline risk factors associated with immune related adverse events and atezolizumab. Front Oncol 2023;13:1138305. [PMID: 36925916 PMCID: PMC10011463 DOI: 10.3389/fonc.2023.1138305] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Accepted: 02/08/2023] [Indexed: 03/08/2023]  Open
Number Cited by Other Article(s)
1
Zhao P, Li J, Yu L, Ma W, Zhao T. Clinical manifestations and risk factors of immune-related thyroid adverse events in patients treated with PD-1 inhibitors: a case-control study. Front Immunol 2025;16:1581057. [PMID: 40356893 PMCID: PMC12066586 DOI: 10.3389/fimmu.2025.1581057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2025] [Accepted: 04/04/2025] [Indexed: 05/15/2025]  Open
2
Savino A, Rossi A, Fagiuoli S, Invernizzi P, Gerussi A, Viganò M. Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives. Cancers (Basel) 2024;17:76. [PMID: 39796705 PMCID: PMC11718971 DOI: 10.3390/cancers17010076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2024] [Revised: 12/26/2024] [Accepted: 12/27/2024] [Indexed: 01/13/2025]  Open
3
Durán-Pacheco G, Chandler GS, Maiya V, Socinski MA, Sonpavde G, Puente J, Essioux L, Carter C, Cardona JV, Mohindra R, Naidoo J. Correlation of safety and efficacy of atezolizumab therapy across indications. J Immunother Cancer 2024;12:e010158. [PMID: 39537212 PMCID: PMC11575237 DOI: 10.1136/jitc-2024-010158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/18/2024] [Indexed: 11/16/2024]  Open
4
Kuczmarski TM, Lynch RC. Managing common toxicities associated with checkpoint inhibitor and chemotherapy combinations for untreated classic Hodgkin lymphoma. Br J Haematol 2024;205:100-108. [PMID: 38698683 DOI: 10.1111/bjh.19478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2024] [Revised: 04/08/2024] [Accepted: 04/09/2024] [Indexed: 05/05/2024]
5
Kawano M, Yano Y, Yamamoto A, Yasutomi E, Inoue Y, Kitadai J, Yoshida R, Matsuura T, Shiomi Y, Ueda Y, Kodama Y. Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy. Diagnostics (Basel) 2024;14:815. [PMID: 38667461 PMCID: PMC11049019 DOI: 10.3390/diagnostics14080815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2024] [Revised: 04/07/2024] [Accepted: 04/12/2024] [Indexed: 04/28/2024]  Open
6
Bedke J, Black PC, Szabados B, Guerrero-Ramos F, Shariat SF, Xylinas E, Brinkmann J, Blake-Haskins JA, Cesari R, Redorta JP. Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition. Urol Oncol 2023;41:461-475. [PMID: 37968169 DOI: 10.1016/j.urolonc.2023.10.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Revised: 09/27/2023] [Accepted: 10/16/2023] [Indexed: 11/17/2023]
7
ZHANG J, CHEN X, MA S. [Advances in Predictive Research of Immune Checkpoint Inhibitors-related 
Adverse Events]. ZHONGGUO FEI AI ZA ZHI = CHINESE JOURNAL OF LUNG CANCER 2023;26:789-794. [PMID: 37989342 PMCID: PMC10663778 DOI: 10.3779/j.issn.1009-3419.2023.106.20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 09/04/2023] [Indexed: 11/23/2023]
8
Rieder D, Trajanoski Z. Checking immunotoxicity risks of checkpoint blockade. NATURE CANCER 2023;4:779-780. [PMID: 37308677 DOI: 10.1038/s43018-023-00561-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA